{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:15:55Z","timestamp":1792026955895,"version":"4.4.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medizinische Universit\u00e4t Wien","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019832","name":"Galapagos NV","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019832","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ard.2025.01.032","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T15:30:35Z","timestamp":1741015835000},"page":"664-679","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update"],"prefix":"10.1016","volume":"84","author":[{"given":"Peter","family":"Nash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kerschbaumer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Konzett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Aletaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"D\u00f6rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Fleischmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jette","family":"Primdahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed","family":"Sattar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Trauner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Winthrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"de Wit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Askling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xenofon","family":"Baraliakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf-Henning","family":"Boehncke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Emery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4528-310X","authenticated-orcid":false,"given":"Laure","family":"Gossec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Krauth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Bong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Maksymowych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Pope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke","family":"Scholte-Voshaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Stamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai-Shan","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Van den Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene","family":"Westhovens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Zeitlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef S.","family":"Smolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ard.2025.01.032_bib0001","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/ni.3731","article-title":"The multiple pathways to autoimmunity","volume":"18","author":"Theofilopoulos","year":"2017","journal-title":"Nat Immunol"},{"issue":"3","key":"10.1016\/j.ard.2025.01.032_bib0002","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/nrg.2015.33","article-title":"Autoimmune diseases - connecting risk alleles with molecular traits of the immune system","volume":"17","author":"Gutierrez-Arcelus","year":"2016","journal-title":"Nat Rev Genet"},{"issue":"1","key":"10.1016\/j.ard.2025.01.032_bib0003","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41594-019-0353-4","article-title":"T cell receptor cross-reactivity between gliadin and bacterial peptides in celiac disease","volume":"27","author":"Petersen","year":"2020","journal-title":"Nat Struct Mol Biol"},{"issue":"5","key":"10.1016\/j.ard.2025.01.032_bib0004","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s41588-018-0102-3","article-title":"Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity","volume":"50","author":"Harley","year":"2018","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.ard.2025.01.032_bib0005","doi-asserted-by":"crossref","first-page":"e28363","DOI":"10.1002\/jmv.28363","article-title":"A common mechanism links Epstein-Barr virus infections and autoimmune diseases","volume":"95","author":"Zhang","year":"2023","journal-title":"J Med Virol"},{"key":"10.1016\/j.ard.2025.01.032_bib0006","doi-asserted-by":"crossref","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"10.1016\/j.ard.2025.01.032_bib0007","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41577-021-00603-1","article-title":"Immune-mediated inflammatory disease therapeutics: past, present and future","volume":"21","author":"McInnes","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"10.1016\/j.ard.2025.01.032_bib0008","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrd1109","article-title":"Therapeutic strategies for rheumatoid arthritis","volume":"2","author":"Smolen","year":"2003","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/j.ard.2025.01.032_bib0009","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/ard-2023-223850","article-title":"Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story","volume":"83","author":"Bonelli","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2025.01.032_bib0010","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41392-020-00312-6","article-title":"Targeting NF-\u03baB pathway for the therapy of diseases: mechanism and clinical study","volume":"5","author":"Yu","year":"2020","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"10.1016\/j.ard.2025.01.032_bib0011","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.3390\/ph16091286","article-title":"Revisiting p38 mitogen-activated protein kinases (MAPK) in inflammatory arthritis: a narrative of the emergence of MAPK-activated protein kinase inhibitors (MK2i)","volume":"16","author":"Ganguly","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"10.1016\/j.ard.2025.01.032_bib0012","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement","volume":"80","author":"Nash","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.ard.2025.01.032_bib0013","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2025.01.032_bib0014","unstructured":"The European Alliance of Associations for Rheumatology. EULAR SOPs \u2013 standard operating procedures for task forces [Internet]. 2024. Available from: https:\/\/wwweularorg\/web\/static\/lib\/pdfjs\/web\/viewerhtml?file=https:\/\/wwweularorg\/document\/download\/702\/412c1a86-96e4-4089-86a6-c6554204c6f9\/679. Accessed January 8, 2024."},{"key":"10.1016\/j.ard.2025.01.032_bib0015","series-title":"OCEBM Levels of Evidence","year":"2011"},{"issue":"3","key":"10.1016\/j.ard.2025.01.032_bib0016","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001374","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research","volume":"6","author":"Kerschbaumer","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.ard.2025.01.032_bib0017","doi-asserted-by":"crossref","unstructured":"Konzett VK, Efficacy of Janus kinase inhibitors in immune-mediated inflammatory diseases a systematic literature review informing the 2024 update of an international consensus statement, https:\/\/doi.org\/10.1016\/j.ard.2025.01.023.","DOI":"10.1016\/j.ard.2025.01.023"},{"key":"10.1016\/j.ard.2025.01.032_bib0018","doi-asserted-by":"crossref","unstructured":"Konzett VK, Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases \u2013 a systematic literature review informing the 2024 update of an international expert consensus statement, https:\/\/doi.org\/10.1016\/j.ard.2025.01.024.","DOI":"10.1016\/j.ard.2025.01.024"},{"issue":"3","key":"10.1016\/j.ard.2025.01.032_bib0019","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/annrheumdis-2021-221276","article-title":"Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database","volume":"81","author":"Taylor","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2025.01.032_bib0020","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002735","article-title":"Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis","volume":"9","author":"Burmester","year":"2023","journal-title":"RMD Open"},{"issue":"3","key":"10.1016\/j.ard.2025.01.032_bib0021","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001395","article-title":"Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme","volume":"6","author":"Cohen","year":"2020","journal-title":"RMD Open."},{"key":"10.1016\/j.ard.2025.01.032_bib0022","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.2147\/PPA.S417677","article-title":"Long-term safety, efficacy, and patient-centered outcomes of filgotinib in the treatment of rheumatoid arthritis: current perspectives","volume":"17","author":"Tanaka","year":"2023","journal-title":"Patient Prefer Adherence"},{"issue":"9","key":"10.1016\/j.ard.2025.01.032_bib0023","doi-asserted-by":"crossref","first-page":"T784","DOI":"10.1016\/j.ad.2023.08.002","article-title":"Long-term safety profile and off-label use of JAK inhibitors in dermatological disorders","volume":"114","author":"Corbella-Bagot","year":"2023","journal-title":"Actas Dermosifiliogr"},{"issue":"4","key":"10.1016\/j.ard.2025.01.032_bib0024","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3390\/medicina59040801","article-title":"Hidradenitis suppurativa and JAK inhibitors: a review of the published literature","volume":"59","author":"Martora","year":"2023","journal-title":"Medicina (Kaunas)"},{"issue":"2","key":"10.1016\/j.ard.2025.01.032_bib0025","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"10.1016\/j.ard.2025.01.032_bib0026","first-page":"1518","article-title":"Efficacy and safety of upadacitinib or elsubrutinib alone or in combination for patients with systemic lupus erythematosus: a phase 2 randomized controlled trial","volume":"76","author":"Merrill","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.ard.2025.01.032_bib0027","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with Covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ard.2025.01.032_bib0028","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1007\/s11357-013-9510-6","article-title":"Redefining meaningful age groups in the context of disease","volume":"35","author":"Geifman","year":"2013","journal-title":"Age (Dordr)"},{"issue":"4","key":"10.1016\/j.ard.2025.01.032_bib0029","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.ard.2025.01.032_bib0030","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.ard.2025.01.032_bib0031","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/ard.2006.066761","article-title":"Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial","volume":"66","author":"Burmester","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2025.01.032_bib0032","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2014-206106","article-title":"Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period","volume":"74","author":"Emery","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.ard.2025.01.032_bib0033","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/gut.2006.099978","article-title":"Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease","volume":"56","author":"Vermeire","year":"2007","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.ard.2025.01.032_bib0034","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/rheumatology\/ket260","article-title":"The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases","volume":"53","author":"Jani","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.ard.2025.01.032_bib0035","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/annrheumdis-2018-213271","article-title":"Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study","volume":"78","author":"Takeuchi","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.ard.2025.01.032_bib0036","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/ecco-jcc\/jjaa249","article-title":"Outcomes of tofacitinib dose reduction in patients with ulcerative colitis in stable remission from the randomised RIVETING trial","volume":"15","author":"Vermeire","year":"2021","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.ard.2025.01.032_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152120","article-title":"Opportunistic infections associated with Janus kinase inhibitor treatment for rheumatoid arthritis: a structured literature review","volume":"58","author":"Winthrop","year":"2023","journal-title":"Semin Arthritis Rheum"},{"issue":"Suppl 1","key":"10.1016\/j.ard.2025.01.032_bib0038","article-title":"POS0092. Herpes zoster in the filgotinib rheumatoid arthritis program","volume":"80","author":"Winthrop","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ard.2025.01.032_bib0039","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1136\/annrheumdis-2021-221051","article-title":"Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years","volume":"81","author":"Winthrop","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ard.2025.01.032_bib0040","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1080\/21645515.2020.1847582","article-title":"A systematic literature review of herpes zoster incidence worldwide","volume":"17","author":"van Oorschot","year":"2021","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"10.1016\/j.ard.2025.01.032_bib0041","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/annrheumdis-2021-220822","article-title":"Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials","volume":"81","author":"Winthrop","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ard.2025.01.032_bib0042","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/ecco-jcc\/jjaa233","article-title":"Tofacitinib for the treatment of ulcerative colitis: analysis of infection rates from the ulcerative colitis clinical programme","volume":"15","author":"Winthrop","year":"2021","journal-title":"J Crohns Colitis"},{"issue":"7","key":"10.1016\/j.ard.2025.01.032_bib0043","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1136\/ard-2022-223636","article-title":"Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study","volume":"82","author":"Huss","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.01.032_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152341","article-title":"Cancer risk with biologic and targeted synthetic DMARDs in patients with rheumatic diseases and previous malignancies: results from the BIOBADASER register","volume":"64","author":"Molina-Collada","year":"2024","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.ard.2025.01.032_bib0045","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/ard-2023-224017","article-title":"Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies","volume":"82","author":"Reinisch","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.ard.2025.01.032_bib0046","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","article-title":"The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation","volume":"75","author":"G\u00f6testam Skorpen","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.ard.2025.01.032_bib0047","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1136\/annrheumdis-2019-216761","article-title":"Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ard.2025.01.032_bib0048","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/annrheumdis-2020-218419","article-title":"Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden","volume":"80","author":"Molander","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.01.032_bib0049","unstructured":"Center for Drug Evaluation and Research. Statistical review \u2013 clinical studies \u2013 olumiant (baricitinib) [Internet]. 2019. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/207924Orig1s000StatR.pdf"},{"issue":"1","key":"10.1016\/j.ard.2025.01.032_bib0050","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/ard-2022-222259","article-title":"Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance","volume":"82","author":"Charles-Schoeman","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.ard.2025.01.032_bib0051","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/ard-2022-223715","article-title":"Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance","volume":"82","author":"Kristensen","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ard.2025.01.032_bib0052","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1136\/ard-2022-222824","article-title":"Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study","volume":"82","author":"Hoisnard","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.ard.2025.01.032_bib0053","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003489","article-title":"Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register","volume":"9","author":"Meissner","year":"2023","journal-title":"RMD Open"},{"issue":"8","key":"10.1016\/j.ard.2025.01.032_bib0054","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1007\/s10620-020-06560-4","article-title":"Characterization of creatine kinase levels in tofacitinib-treated patients with ulcerative colitis: results from clinical trials","volume":"66","author":"Panaccione","year":"2021","journal-title":"Dig Dis Sci"},{"issue":"1","key":"10.1016\/j.ard.2025.01.032_bib0055","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40744-023-00624-3","article-title":"Impact of upadacitinib on laboratory parameters and related adverse events in patients with RA: integrated data up to 6.5 years","volume":"11","author":"Charles-Schoeman","year":"2024","journal-title":"Rheumatol Ther"},{"issue":"3","key":"10.1016\/j.ard.2025.01.032_bib0056","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1136\/annrheumdis-2020-218510","article-title":"Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme","volume":"80","author":"Cohen","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.ard.2025.01.032_bib0057","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1136\/annrheumdis-2019-216852","article-title":"Infections in baricitinib clinical trials for patients with active rheumatoid arthritis","volume":"79","author":"Winthrop","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2025.01.032_bib0058","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ard.2025.01.032_bib0059","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/annrheumdis-2021-221916","article-title":"Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial","volume":"81","author":"Araujo","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ard.2025.01.032_bib0060","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/art.42318","article-title":"A multicenter, prospective, randomized, parallel-group trial on the effects of temporary methotrexate discontinuation for one week versus two weeks on seasonal influenza vaccination in patients with rheumatoid arthritis","volume":"75","author":"Park","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"10.1016\/j.ard.2025.01.032_bib0061","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41584-019-0279-6","article-title":"Remission in rheumatoid arthritis: missing objectives by using inadequate DAS28 targets","volume":"15","author":"Aletaha","year":"2019","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2025.01.032_bib0062","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/ard-2022-223413","article-title":"American College of Rheumatology\/EULAR remission criteria for rheumatoid arthritis: 2022 revision","volume":"82","author":"Studenic","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2025.01.032_bib0063","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/annrheumdis-2013-203559","article-title":"Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials","volume":"73","author":"Sieper","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ard.2025.01.032_bib0064","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.berh.2018.08.004","article-title":"Disease activity assessment in patients with psoriatic arthritis","volume":"32","author":"Kerschbaumer","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"16","key":"10.1016\/j.ard.2025.01.032_bib0065","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","article-title":"Trial of upadacitinib or abatacept in rheumatoid arthritis","volume":"383","author":"Rubbert-Roth","year":"2020","journal-title":"N Engl J Med"},{"issue":"Suppl 9","key":"10.1016\/j.ard.2025.01.032_bib0066","first-page":"1683","article-title":"CRP changes during bacterial infections in baricitinib-treated patients with RA","volume":"70","author":"Hendricks","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"10.1016\/j.ard.2025.01.032_bib0067","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/art.41384","article-title":"Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, multi-country, randomized, double-blind, active comparator-controlled trial","volume":"72","author":"van Vollenhoven","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2025.01.032_bib0068","first-page":"275","article-title":"Efficacy and safety of upadacitinib in patients with psoriatic arthritis: 2-year results from the phase 3 SELECT-PsA 1 study","volume":"10","author":"McInnes","year":"2023","journal-title":"Rheumatol Ther"},{"issue":"11","key":"10.1016\/j.ard.2025.01.032_bib0069","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1136\/ard-2022-222405","article-title":"Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial","volume":"81","author":"Balanescu","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2025.01.032_bib0070","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1136\/annrheumdis-2020-218992","article-title":"Age-based (<65 vs \u226565 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry","volume":"80","author":"Winthrop","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ard.2025.01.032_bib0071","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1136\/ard-2022-222543","article-title":"Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial","volume":"82","author":"Curtis","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.ard.2025.01.032_bib0072","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/art.42250","article-title":"Tofacitinib and risk of malignancy: results from the safety of tofacitinib in routine care patients with rheumatoid arthritis (STAR-RA) study","volume":"74","author":"Khosrow-Khavar","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 1","key":"10.1016\/j.ard.2025.01.032_bib0073","first-page":"1417","article-title":"AB0454: safety of filgotinib in patients with RA: laboratory analysis results from a long-term extension study","volume":"82","author":"Favalli","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"10.1016\/j.ard.2025.01.032_bib0074","doi-asserted-by":"crossref","first-page":"i525","DOI":"10.1093\/ecco-jcc\/jjac190.0523","article-title":"P393 effect of filgotinib on anaemia in patients with ulcerative colitis in SELECTION","volume":"17","author":"Loveikyte","year":"2023","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.ard.2025.01.032_bib0075","doi-asserted-by":"crossref","unstructured":"Kay J, Harigai M, Rancourt J, Dickson C, Melby T, Issa M, et al. Changes in selected haematological parameters associated with JAK1\/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib. RMD Open. 2020;6(3):e001370 doi:10.1136\/rmdopen-2020-001370","DOI":"10.1136\/rmdopen-2020-001370"},{"issue":"4","key":"10.1016\/j.ard.2025.01.032_bib0076","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s41584-024-01093-w","article-title":"TYK2: an emerging therapeutic target in rheumatic disease","volume":"20","author":"Morand","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"Suppl 1","key":"10.1016\/j.ard.2025.01.032_bib0077","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1136\/annrheumdis-2022-eular.1862","article-title":"POS1040: safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor: as assessed by laboratory parameters \u2013 results from a phase 2 trial in psoriatic arthritis and 2 phase 3 trials in psoriasis","volume":"81","author":"Fleischmann","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.ard.2025.01.032_bib0078","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1111\/jdv.19925","article-title":"Deucravacitinib in moderate-to-severe plaque psoriasis: pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2)","volume":"38","author":"Strober","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.ard.2025.01.032_bib0079","first-page":"201","article-title":"Evaluation of VTE, MACE, and serious infections among patients with RA treated with baricitinib compared to TNFi: a multi-database study of patients in routine care using disease registries and claims databases","volume":"10","author":"Salinas","year":"2023","journal-title":"Rheumatol Ther"},{"issue":"2","key":"10.1016\/j.ard.2025.01.032_bib0080","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/ard-2022-223050","article-title":"Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis","volume":"82","author":"Molander","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2025.01.032_bib0081","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamadermatol.2023.4090","article-title":"Cardiovascular and venous thromboembolic risk with JAK inhibitors in immune-mediated inflammatory skin diseases: a systematic review and meta-analysis","volume":"160","author":"Ingrassia","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"12","key":"10.1016\/j.ard.2025.01.032_bib0082","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1001\/jamadermatol.2023.3830","article-title":"Janus kinase inhibitors and adverse events of acne: a systematic review and meta-analysis","volume":"159","author":"Martinez","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.ard.2025.01.032_bib0083","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/annrheumdis-2021-221366","article-title":"2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19","volume":"81","author":"Alunno","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ard.2025.01.032_bib0084","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001595","article-title":"Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure","volume":"7","author":"Burmester","year":"2021","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.ard.2025.01.032_bib0085","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2022.2161812","article-title":"Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials","volume":"34","author":"Bieber","year":"2023","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"10.1016\/j.ard.2025.01.032_bib0086","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/bjd\/ljac059","article-title":"Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials","volume":"188","author":"King","year":"2023","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.ard.2025.01.032_bib0087","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jaci.2022.09.023","article-title":"Safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis of phase 3 studies","volume":"151","author":"Guttman-Yassky","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"Suppl 1","key":"10.1016\/j.ard.2025.01.032_bib0088","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1136\/annrheumdis-2023-eular.1553","article-title":"POS0844: integrated safety analysis of filgotinib in patients with moderate to severe active rheumatoid arthritis with a maximum exposure of 8.3 years","volume":"82","author":"Winthrop","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ard.2025.01.032_bib0089","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41584-023-01062-9","article-title":"Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician","volume":"20","author":"Szekanecz","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.ard.2025.01.032_bib0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104840","article-title":"Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors","volume":"97","author":"Jensen","year":"2023","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.ard.2025.01.032_bib0091","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.ard.2025.01.032_bib0092","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 program for evaluation of TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.ard.2025.01.032_bib0093","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.mayocp.2023.08.029","article-title":"Real-world clinical equivalence of generic and branded tofacitinib: a prospective longitudinal cohort study in patients with rheumatoid arthritis","volume":"99","author":"Zhao","year":"2024","journal-title":"Mayo Clin Proc"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725001815?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725001815?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T08:50:50Z","timestamp":1749804650000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496725001815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":93,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0003496725001815"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2025.01.032","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2025.01.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}